Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Rotterdam, Netherlands Clinical Trials

A listing of Rotterdam, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (44) clinical trials

A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma

Study KTE-C19-102 is a phase 2, multicenter, open-label study evaluating the efficacy of KTE-X19 in subjects with Relapsed/Refractory MCL

Phase

0.0 miles

Learn More »

Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma

Study E7080-G000-218 is a Randomized, open-label (formerly Double-blind), Phase 2 Trial conducted to assess whether a starting dose of lenvatinib 14 milligrams (mg) in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety ...

Phase

0.0 miles

Learn More »

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab

Antibodies that target the crosstalk between immune and cancer cells by inhibiting programmed death 1 (PD-1, pembrolizumab and durvalumab) or programmed death-ligand 1 (PD-L1, atezolizumab) have shown promising results as second-line treatments in phase II studies with response rates of about 30%. Although urothelial cancer is prone to immune checkpoint ...

Phase

0.0 miles

Learn More »

Vemurafenib Plus Cobimetinib in Metastatic Melanoma

Molecular targeted therapy with BRAF inhibitor vemurafenib is now currently used as first line treatment for patients with unresectable stage IIIc or metastatic melanoma harboring the BRAFV600 mutation, which is present in about 50% of melanoma patients. Despite the improvement in Progression Free Survival (PFS) en Overall Survival (OS) compared ...

Phase

0.0 miles

Learn More »

Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD

This will be a phase II, multi-centre, randomized, double-blind, placebo-controlled study designed to assess preliminary efficacy, safety and pharmacokinetics (PK) of 2-7 days continuous IV administration of sevuparin for the management of acute VOC in subjects with SCD. Adults and adolescents 12 years of age will be randomized to treatment ...

Phase

0.0 miles

Learn More »

Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Atezolizumab, a humanized monoclonal antibody that targets human programmed deathligand 1 (PD-L1) has shown activity in TNBC. Early clinical trials with anti-PD-(L)1 monotherapy have shown that the median duration to response in TNBC is remarkably long (18 weeks) compared to cytotoxic chemotherapy. Since advanced TNBC is characterized by rapid disease ...

Phase

0.0 miles

Learn More »

Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation

The device is a dynamic annuloplasty ring/band that is able to be adjusted in order to correct for mitral regurgitation intraoperatively or postoperatively, off-pump.

Phase

0.0 miles

Learn More »

2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)

Open randomized multicenter phase II study in patiënts in need of 2nd line treatment for advanced/metastatic NSCLC. Efficacy and safety of monotherapy with erlotinib will be compared with combination therapy of erlotinib and chemotherapy. In recent studies it was established that pemetrexed activity is more pronounced in non-squamous NSCLC in ...

Phase

0.0 miles

Learn More »

Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

After failure on docetaxel, which has been the standard first line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), several treatment options are currently available. Two of the treatment options are directed against the androgen receptor (AR), enzalutamide and abiraterone. A third option is cabazitaxel, a next generation taxane. ...

Phase

0.0 miles

Learn More »

INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)

Subjects eligible to participate in the study must provide written informed consent (IC) before randomization or any study- specific procedures. The study consists of 2 parts (PART A and PART B) as described below: PART A: has an open-label, randomized, multicenter design to evaluate the feasibility of administration of inhaled ...

Phase

0.0 miles

Learn More »